Jay S. Duker M.D.
Net Worth

Last updated:

What is Jay S. Duker M.D. net worth?

The estimated net worth of Dr. Jay S. Duker M.D. is at least $390,810 as of 10 Jul 2024. He owns shares worth $193,200 as insider and has received compensation worth at least $197,610 in EyePoint Pharmaceuticals, Inc..

What is the salary of Jay S. Duker M.D.?

Dr. Jay S. Duker M.D. salary is $28,230 per year as Chief Operating Officer in EyePoint Pharmaceuticals, Inc..

How old is Jay S. Duker M.D.?

Dr. Jay S. Duker M.D. is 66 years old, born in 1959.

What stocks does Jay S. Duker M.D. currently own?

As insider, Dr. Jay S. Duker M.D. owns shares in one company:

Company Title Shares Price per share Total value
EyePoint Pharmaceuticals, Inc. (EYPT) Chief Operating Officer 17,500 $11.04 $193,200

What does EyePoint Pharmaceuticals, Inc. do?

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EYPT logo
EYPT
EyePoint Pharmaceuticals, Inc.
$11.04

Jay S. Duker M.D. insider trading

EyePoint Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 16,666 N/A N/A
Option
Restricted Stock Units 16,666 N/A N/A
Option
Restricted Stock Units 7,000 N/A N/A
Option
Common Stock 7,000 N/A N/A
Option
Restricted Stock Units 4,967 N/A N/A
Option
Common Stock 4,967 N/A N/A
Option
Common Stock 20,793 N/A N/A
Option
Restricted Stock Units 20,793 N/A N/A
Option
Common Stock 4,967 N/A N/A
Option
Restricted Stock Units 4,967 N/A N/A
Option
Restricted Stock Units 7,000 N/A N/A
Option
Common Stock 7,000 N/A N/A
Option
Common Stock 15,258 N/A N/A
Option
Restricted Stock Units 15,258 N/A N/A
Option
Restricted Stock Units 4,966 N/A N/A
Option
Common Stock 4,966 N/A N/A
Option
Deferred Stock Units 6,667 N/A N/A
Option
Common Stock 6,667 N/A N/A
Option
Stock Option (Right to Buy) 20,000 $1.77 $35,400
Option
Common Stock 20,000 $1.77 $35,400
Purchase
Common Stock 5,000 $1.89 $9,450
Option
Common Stock 12,500 N/A N/A
Option
Deferred Stock Units 12,500 N/A N/A

EyePoint Pharmaceuticals key executives

EyePoint Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: